Skip to the page content
Your donations
Check before you give

Warszawski Uniwrsytet Medyczny

EIN 98-0674509 · Poland

Public records raise at least one point you should look into before giving.

LegitimacyCautionRegistration and standingFinancial healthFair65 out of 100GovernanceGood75 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

Warszawski Uniwersytet Medyczny as a public charity refers its activities to education and scientific goals. Its mission is to educate students for practising medicine, dentistry, nursing, midwifery, physiotherapy and pharmacy. The main activity is conducted at four academic faculties. Also university education activities include a range of postgraduate training: doctoral studies, specialization and postgraduate courses in numerous fields.

Income
$163.9 million
Spending
$159.7 million
Spent on programs
100%
Reserves
0.1 months of spending
Largest source of income
government grants, 70%
Employees
0
Volunteers
15
Highest pay
$124,469, officer

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Fair: 65 out of 100. Higher than 53% of charities in its peer group (education, over $100m).

  • Reserves

    4 of 35

    Spendable reserves would cover 0.1 months of spending.

  • Debt

    16 of 20

    It owes 16% of what it owns.

  • Living within its means

    15 of 15

    Income exceeded spending by 3% of income.

  • Income trend

    15 of 15

    Income rose 2% on the year before.

  • Spending floor

    15 of 15

    100% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Good: 75 out of 100. Higher than 3% of charities in its peer group (education, over $100m).

  • Independent board

    25 of 25

    50 of 50 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    0 of 8

    Reports no written whistleblower policy.

  • Record keeping policy

    0 of 7

    Reports no written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    0 of 10

    Did not give the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (4)
  1. $869,379 spent. ABM05 EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial). The aim of this project is to evaluate: 1) the effect of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical endpoints in patients with acute/decompensated heart failure (AHF); 2) the effect of SGLT-2 inhibitors on cardiac function; 3) the effect of SGLT-2 inhibitors on biomarkers and circulating microRNAs (miRNAs) and microbiome metabolites; 4) to propose a risk prediction score for close monitoring of the course of AHF and its treatment with SGLT-2 inhibitors based on selected miRNAs and biomarkers associated with molecular pathways associated with disease progression.
  2. $551,069 spent. ABM11 Assessment of the incidence of persistent pulmonary hypertension of the newborn in a group of newborns born between 32 and 42 weeks of gestation treated with salbutamol -The primary objective of the clinical trial will be to assess the incidence of PPHN (PPHN-persistent pulmonary hypertension of the newborn) defined as the need for ventilation with FiO2 > 0.50 and echocardiographic signs of increased pulmonary pressure (left-right or bidirectional shunt through a patent ductus arteriosus) or the need for ventilation with FiO2 > 0.50 and a difference in pre- and post-ductal saturation > 20%) in the treatment of respiratory failure in a group of newborns born between 32 and 41 weeks of gestation. The secondary objectives will be to assess the modified Silverman scale, hereinafter referred to as the "TTN scale" in comparison to the concentration of oxygen used during ventilation and the intervention used, and to assess the parameters of the acid-base balance test: pH, carbon dioxide tension (pCO2), base deficiency (BE) in the compared groups. The study was planned as a prospective, multicenter, double-blind, randomized, placebo-controlled study.
  3. $433,335 spent. ABM03 A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC). The aim of the presented IMPROVE-MC study is to evaluate the efficacy and safety of 12 months of immunosuppressive treatment with prednisone and azathioprine compared to placebo, in combination with standard therapy, in patients with virus-negative inflammatory cardiomyopathy/cardiomyopathy. An additional goal of the project is to create a diagnostic and therapeutic protocol ready for implementation in Polish and global healthcare systems, enabling modification of treatment guidelines for inflammatory cardiomyopathy.
  4. $157.9 million spent. Other program services

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.

  3. Are donations tax-deductible? Caution.

    The IRS master file records contributions to this 501(c)(3) charitable organization as not deductible.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2024.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since May 2013.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.